Drug Delivery Infusion System Market Size & Industry Outlook
The global drug delivery infusion system market size reached US$ 12.80 Billion with rise of US$ 13.55 Billion in 2024 is expected to reach US$ 22.62 Billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033. A major growth driver in the global drug delivery infusion system market is technological advancement, particularly the development of precision IV pumps. In April 2025, ICU Medical Inc. received FDA 510(k) clearance for its Plum Solo and updated Plum Duo pumps under the IV Performance Platform, designed to reduce delivery variability and achieve ±3% accuracy in real-world conditions while ensuring reliable documentation. This instance highlights how innovation aimed at improving accuracy and reliability not only enhances patient safety but also accelerates the adoption of advanced infusion systems, making technology a cornerstone of market expansion.
Key Highlights
North America dominates the drug delivery infusion system market with the largest revenue share of 42.5% in 2024.
The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 8.1% over the forecast period.
Based on product type, volumetric infusion pumps segment led the market with the largest revenue share of 39.6% in 2024.
The major market players in the Medtronic, Eitan Medical, B. Braun SE, BD, Baxter, Terumo Corporation, Insulet Corporation, Fresenius Kabi AG, Arcomed, ICU Medical, Inc and among others.
Market Dynamics
Drivers: The rise in the prevalence of chronic diseases is significantly driving the drug delivery infusion system market growth
One of the strongest growth drivers in the global drug delivery infusion system market is the rising prevalence of chronic diseases that require long-term and precise treatment management. Chronic illnesses such as diabetes, cancer, and cardiovascular disorders are steadily increasing worldwide, creating sustained demand for infusion-based therapies to deliver medications, nutrition, and pain management solutions with accuracy and safety.
For instance, according to the World Health Organization (WHO), chronic diseases are responsible for nearly 74% of all global deaths, with diabetes alone affecting over 537 million adults worldwide in 2024, a number projected to rise to 643 million by 2030. Similarly, the International Agency for Research on Cancer (IARC) reported that in 2024 there were around 20 million new cancer cases globally, many of which require infusion-based chemotherapy or supportive treatments. Similarly, insulin infusion pumps are becoming increasingly vital in managing diabetes patients who require consistent glucose control, especially with rising cases among younger populations.
Restraints: Risk of medication errors and device malfunctions are hampering the growth of the drug delivery infusion system market
The global drug delivery infusion system market faces significant restraints due to the risk of medication errors and device malfunctions, which pose safety concerns for patients and healthcare providers. These issues can lead to overdosing, underdosing, or therapy delays. The FDA's MAUDE database reports thousands of adverse event reports related to infusion pumps annually, often linked to errors in use or device malfunctions. These incidents compromise patient safety, increase hospital liabilities, and erode trust in advanced infusion technologies. Consequently, regulatory bodies impose stringent safety requirements, which can delay product approvals and limit widespread adoption.
For more details on this report – Request for Sample
Drug Delivery Infusion System Market, Segment Analysis
The global drug delivery infusion system market is segmented based on product type, application, end user, and region.
Product Type:The volumetric infusion pumps from product type segment are expected to dominate the drug delivery infusion system market with a 39.6% share in 2024
Volumetric infusion pumps are a widely adopted product segment in the global drug delivery infusion system market due to their ability to deliver large volumes of fluids, medications, and nutrients with precision and consistency. They are increasingly used in critical care, oncology, and surgical settings, where accurate and continuous drug administration is crucial. The demand for advanced hospital infrastructure and the increasing number of patients requiring long-term infusion therapies for chronic diseases like cancer and cardiovascular disorders drives this segment's growth.
For instance, in August 2025, Terumo India, the Indian subsidiary of Terumo Corporation, has introduced Terufusion Advanced Infusion Systems for the first time in India, featuring a Smart Syringe Pump, Smart Infusion Pump (volumetric), and Pump Monitoring System software.
Application:The oncology segment is estimated to have a 35.1% of the drug delivery infusion system market share in 2024
The oncology application segment is crucial in the global drug delivery infusion system market, as cancer treatment requires precise, continuous, and controlled drug delivery. Infusion pumps are essential for safe dosing over extended periods, especially for complex drug regimens. Volumetric and syringe infusion pumps are widely used, while implantable and ambulatory pumps are increasingly preferred for long-term or home-based cancer care. For instance, the rising global cancer burden, with 20 million new cases in 2024, translates into higher demand for infusion systems in oncology departments, as hospitals and specialized centers expand capacity for safe and efficient chemotherapy delivery.
Geographical Analysis
North America is expected to dominate the global drug delivery infusion system market with a 42.5% in 2024
North America remains the leading regional market for drug-delivery infusion systems due to a mature healthcare infrastructure, high public and private healthcare spending, rapid adoption of advanced medical technologies, and a strong presence of major device manufacturers and suppliers. These factors combine to drive early adoption of smart pumps, integrations with hospital IT systems, and large hospital procurement budgets that sustain market leadership.
For instance, in April 2025, ICU Medical received FDA 510(k) clearance for several major additions to its infusion pump portfolio, marking the initial launch of its IV Performance Platform.
The United States is by far the largest country market in North America accounting for the vast majority of regional revenues because of its high incidence of chronic disease, extensive acute-care capacity, robust R&D and favorable reimbursement environment that support rapid uptake of advanced infusion products. Reports show the U.S. contributed the lion’s share of North American infusion-pump revenue in recent years.
Europe is the second region after North America which is expected to dominate the global drug delivery infusion system market with a 34.5% in 2024
Europe represents a key market in the global drug delivery and infusion systems landscape, driven by well-established healthcare infrastructures and a highly organized network of hospitals. The region benefits from stringent regulatory standards and robust safety frameworks, which ensure high-quality patient care and reliable adoption of advanced medical technologies. Over recent years, there has been a noticeable shift toward home-infusion therapies, reflecting increasing patient preference for outpatient care, cost containment, and improved convenience.
Among European countries, Germany stands out as a particularly influential market. Its healthcare system is distinguished by advanced infrastructure, substantial investment in hospitals, and a thriving medical technology sector that fosters innovation. These factors collectively facilitate the rapid procurement and deployment of sophisticated infusion systems, positioning Germany as a pivotal hub for the adoption and growth of drug delivery solutions in Europe.
The Asia Pacific region is the fastest-growing region in the global drug delivery infusion system market, with a CAGR of 8.1% in 2024
The Asia-Pacific region is emerging as a rapidly growing market for drug delivery and infusion systems, propelled by rising healthcare expenditure, expanding hospital networks, and increasing patient demand for advanced therapies. Countries in this region are witnessing gradual adoption of home-infusion services, driven by the need for convenient, cost-effective, and patient-centric care.
Among these, Japan stands out as a major growth driver due to its highly developed healthcare infrastructure, technologically advanced medical device industry, and strong government support for healthcare innovation. The country’s aging population and high prevalence of chronic diseases further fuel the demand for infusion systems, both in hospitals and at home. Japanese healthcare providers are increasingly adopting sophisticated, automated infusion devices that enhance treatment precision and patient safety, setting a benchmark for the wider Asia-Pacific market.
For instance, in May 2025, UCB, a global biopharmaceutical company, has announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved at-home self-administration of RYSTIGGO (rozanolixizumab) for people living with generalized Myasthenia Gravis (gMG). Patients can now self-administer the therapy at home using either an infusion pump or a new manual push syringe method, following proper training from a healthcare professional.
Competitive Landscape
Top companies in the drug delivery infusion system market include Medtronic, Eitan Medical, B. Braun SE, BD, Baxter, Terumo Corporation, Insulet Corporation, Fresenius Kabi AG, Arcomed, ICU Medical, Inc and among others.
Medtronic: Medtronic is a major global player in the global drug delivery infusion system market, offering a diverse portfolio that includes insulin, volumetric, syringe, and implantable pumps. Its MiniMed insulin pumps are widely used worldwide, and strategic acquisitions like EOFlow expand its capabilities in wearable and home-infusion devices. With a strong focus on innovation and comprehensive solutions, Medtronic continues to shape the competitive landscape and drive growth in the global drug delivery infusion system market
Key Developments:
In June 2025, TriSalus Life Sciences unveiled the TriNav FLX Infusion System, featuring enhanced trackability with twice the flexible material at the distal tip. This improvement enables smoother and more efficient navigation through intricate and winding blood vessels.
In April 2025, ICU Medical secured FDA 510(k) clearance for significant additions to its infusion pump lineup, marking the rollout of its IV Performance Platform. The new approvals cover the Plum Solo precision IV pump, a single-channel device designed to complement the dual-channel Plum Duo, along with updated versions of the Plum Duo pump and the LifeShield infusion safety software.
Market Scope
Metrics | Details | |
CAGR | 6.8% | |
Market Size Available for Years | 2022-2033 | |
Estimation Forecast Period | 2025-2033 | |
Revenue Units | Value (US$ Bn) | |
Segments Covered | Product Type | Volumetric Infusion Pumps, Syringe Infusion Systems, Ambulatory Infusion Systems, Implantable Infusion Systems, Insulin Infusion Pumps, Enteral Infusion Systems, Others |
Application | Diabetes Management, Analgesia, Clinical Nutrition, Hematology, Pediatrics, Others | |
End User | Hospitals, Specialty Clinics, Ambulatory Surgery Centers, Others | |
Regions Covered | North America, Europe, Asia-Pacific, South America and the Middle East & Africa | |
The global drug delivery infusion system market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
For more medical devices-related reports, please click here
